Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin + ifosfamide with or without sintilimab for advanced pleomorphic undifferentiated sarcoma
ChiCTR2500104726Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in Malignant Fibrous Histiocytoma (MFH) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Malignant Fibrous Histiocytoma (MFH)
Beyond the preview
Go deeper on ChiCTR2500104726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104726.